Recurrent Melanoma Recruiting Phase 2 Trials for DB09073 (Palbociclib)

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02465060NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple MyelomaTreatment
NCT01037790PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCERTreatment